Disposition of epirubicin and metabolites with repeated courses to cancer patients.
Thirteen cancer patients were studied following a total of 41 courses of epirubicin (EPI) (38-50 mg.m-2, mean 49.2 mg.m-2, administered by a 60 min infusion), together with other cancer chemotherapeutic agents. The aim was to consider the disposition of EPI and metabolites following subsequent courses as it has been reported that doxorubicin (the 4'-epimer parent of EPI) clearance is increased following the first administration. We have observed that EPI-glucuronide accounted for a mean 78.0%, epirubicinol 0.2% and epirubicinol-glucuronide 19.3% and that parent EPI accounted for only 2.4% of the EPI-compounds measured (mean of all patients and courses) for the 3 h period immediately following the infusion. These data confirm the rapid metabolism of EPI and the dominance of the glucuronidation metabolite pathway (which is not available to doxorubicin) and are compared with the metabolite profile observed in other reports. Large inter- and intra-individual variability in area under the plasma concentration/time curve were observed with no clear evidence of any consistent directional trend for such fluctuations, suggesting that factors contributing to EPI disposition are multivariate.
Morris
R G
RG
Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville South, South Australia.
Kotasek
D
D
Paltridge
G
G
D000328:Adult; D000368:Aged; D015251:Epirubicin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005965:Glucuronates / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*
D005965:Glucuronates; D015251:Epirubicin